101 related articles for article (PubMed ID: 10989697)
1. Antiviral effect of the combination of enviroxime and disoxaril on coxsackievirus B1 infection.
Nikolaeva L; Galabov AS
Acta Virol; 2000 Apr; 44(2):73-8. PubMed ID: 10989697
[TBL] [Abstract][Full Text] [Related]
2. Synergistic drug combinations against the in vitro replication of Coxsackie B1 virus.
Nikolaeva-Glomb L; Galabov AS
Antiviral Res; 2004 Apr; 62(1):9-19. PubMed ID: 15026197
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxicity of the synergistic antienteroviral combination of enviroxime and disoxaril.
Nikolaeva L; Galabov AS
Acta Virol; 1999 Aug; 43(4):263-5. PubMed ID: 10749374
[TBL] [Abstract][Full Text] [Related]
4. Synergistic inhibitory effect of enviroxime and disoxaril on poliovirus type 1 replication.
Nikolaeva L; Galabov AS
Acta Virol; 1995 Dec; 39(5-6):235-41. PubMed ID: 8722291
[TBL] [Abstract][Full Text] [Related]
5. In vitro inhibitory effects of dual combinations of picornavirus replication inhibitors.
Nikolaeva L; Galabov AS
Acta Virol; 1999 Oct; 43(5):303-11. PubMed ID: 10757231
[TBL] [Abstract][Full Text] [Related]
6. Disoxaril mutants of Coxsackievirus B1: phenotypic characteristics and analysis of the target VP1 gene.
Nikolova I; Galabov AS; Petkova R; Chakarov S; Atanasov B
Z Naturforsch C J Biosci; 2011; 66(11-12):627-36. PubMed ID: 22351989
[TBL] [Abstract][Full Text] [Related]
7. Development of resistance to disoxaril in Coxsackie B1 virus-infected newborn mice.
Nikolova I; Galabov AS
Antiviral Res; 2003 Sep; 60(1):35-40. PubMed ID: 14516919
[TBL] [Abstract][Full Text] [Related]
8. Anti-enteroviral triple combination of viral replication inhibitors: activity against coxsackievirus B1 neuroinfection in mice.
Stoyanova A; Nikolova I; Pürstinger G; Dobrikov G; Dimitrov V; Philipov S; Galabov AS
Antivir Chem Chemother; 2015 Dec; 24(5-6):136-147. PubMed ID: 27815331
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of the Consecutive Alternating Administration Course of a Triple Antiviral Combination in Coxsackievirus B3 Infections in Mice.
Vassileva-Pencheva R; Galabov AS
Drug Res (Stuttg); 2016 Dec; 66(12):639-643. PubMed ID: 27552486
[TBL] [Abstract][Full Text] [Related]
10. Effect of consecutive alternating administration (CAA) of a triple anti-enteroviral combination on Coxsackievirus B1 neuroinfection in mice.
Stoyanova A; Nikolova I; Galabov AS
Antiviral Res; 2015 Sep; 121():138-44. PubMed ID: 26196747
[TBL] [Abstract][Full Text] [Related]
11. Antiviral Combination Approach as a Perspective to Combat Enterovirus Infections.
Galabov AS; Nikolova I; Vassileva-Pencheva R; Stoyanova A
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(2):91-9. PubMed ID: 27442375
[TBL] [Abstract][Full Text] [Related]
12. Combination of soluble coxsackievirus-adenovirus receptor and anti-coxsackievirus siRNAs exerts synergistic antiviral activity against coxsackievirus B3.
Werk D; Pinkert S; Heim A; Zeichhardt H; Grunert HP; Poller W; Erdmann VA; Fechner H; Kurreck J
Antiviral Res; 2009 Sep; 83(3):298-306. PubMed ID: 19591879
[TBL] [Abstract][Full Text] [Related]
13. Avoiding drug-resistance development by novel approach of combining anti-enteroviral substances against coxsackievirus B1 infection in mice.
Vassileva-Pencheva R; Galabov AS
Antiviral Res; 2010 Feb; 85(2):366-72. PubMed ID: 19900482
[TBL] [Abstract][Full Text] [Related]
14. Combination treatment with ribavirin and interferon for coxsackievirus B3 replication.
Okada I; Matsumori A; Matoba Y; Tominaga M; Yamada T; Kawai C
J Lab Clin Med; 1992 Oct; 120(4):569-73. PubMed ID: 1328433
[TBL] [Abstract][Full Text] [Related]
15. QiHong prevents death in coxsackievirus B3 induced murine myocarditis through inhibition of virus attachment and penetration.
Song X; Liu Z; Wang H; Xin Y; Wang X; Chen J; Shi Y; Zhang C; Hui R
Exp Biol Med (Maywood); 2007 Dec; 232(11):1441-8. PubMed ID: 18040068
[TBL] [Abstract][Full Text] [Related]
16. QSAR analysis of [(biphenyloxy)propyl]isoxazoles: agents against coxsackievirus B3.
Muratov EN; Varlamova EV; Artemenko AG; Khristova T; Kuz'min VE; Makarov VA; Riabova OB; Wutzler P; Schmidtke M
Future Med Chem; 2011 Jan; 3(1):15-27. PubMed ID: 21428823
[TBL] [Abstract][Full Text] [Related]
17. Therapy of coxsackie virus B3-induced myocarditis with WIN 54954 in different formulations.
Pauksen K; Ilbäck NG; Friman G; Fohlman J
Scand J Infect Dis Suppl; 1993; 88():125-30. PubMed ID: 8390715
[TBL] [Abstract][Full Text] [Related]
18. Xiao chai hu tang inhibits CVB1 virus infection of CCFS-1 cells through the induction of Type I interferon expression.
Cheng PW; Ng LT; Lin CC
Int Immunopharmacol; 2006 Jun; 6(6):1003-12. PubMed ID: 16644487
[TBL] [Abstract][Full Text] [Related]
19. Bupleurum kaoi inhibits Coxsackie B virus type 1 infection of CCFS-1 cells by induction of type I interferons expression.
Cheng PW; Chiang LC; Yen MH; Lin CC
Food Chem Toxicol; 2007 Jan; 45(1):24-31. PubMed ID: 17052829
[TBL] [Abstract][Full Text] [Related]
20. Eradication of persistent coxsackievirus B infection from a pancreatic cell line with clinically used antiviral drugs.
Honkimaa A; Sioofy-Khojine AB; Oikarinen S; Bertin A; Hober D; Hyöty H
J Clin Virol; 2020 Jul; 128():104334. PubMed ID: 32450550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
